Liu Meng, Chen Jiasheng, Cao Nailong, Zhao Weixin, Gao Guo, Wang Ying, Fu Qiang
Department of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Eastern Institute of Urologic Reconstruction, Shanghai Jiao Tong University, Shanghai 200233, China.
Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC 27157, USA.
Pharmaceutics. 2022 Oct 19;14(10):2229. doi: 10.3390/pharmaceutics14102229.
Lower urinary tract dysfunction often requires tissue repair or replacement to restore physiological functions. Current clinical treatments involving autologous tissues or synthetic materials inevitably bring in situ complications and immune rejection. Advances in therapies using stem cells offer new insights into treating lower urinary tract dysfunction. One of the most frequently used stem cell sources is adipose tissue because of its easy access, abundant source, low risk of severe complications, and lack of ethical issues. The regenerative capabilities of adipose-derived stem cells (ASCs) in vivo are primarily orchestrated by their paracrine activities, strong regenerative potential, multi-differentiation potential, and cell-matrix interactions. Moreover, biomaterial scaffolds conjugated with ASCs result in an extremely effective tissue engineering modality for replacing or repairing diseased or damaged tissues. Thus, ASC-based therapy holds promise as having a tremendous impact on reconstructive urology of the lower urinary tract.
下尿路功能障碍通常需要组织修复或置换以恢复生理功能。目前涉及自体组织或合成材料的临床治疗不可避免地会带来原位并发症和免疫排斥反应。利用干细胞的治疗进展为治疗下尿路功能障碍提供了新的思路。最常用的干细胞来源之一是脂肪组织，因为其易于获取、来源丰富、严重并发症风险低且不存在伦理问题。脂肪来源干细胞（ASC）在体内的再生能力主要由其旁分泌活性、强大的再生潜力、多分化潜力以及细胞-基质相互作用来调控。此外，与ASC结合的生物材料支架形成了一种极其有效的组织工程模式，用于替换或修复患病或受损组织。因此，基于ASC的治疗有望在下尿路重建泌尿外科领域产生巨大影响。
